A Phase III clinical trial is now underway in the pivotal study of interferon alfa-2b gene therapy in pleural mesothelioma. After promising results from the Phase II clinical trial, scientists and researchers are hopeful they are just one step away from FDA approval for this cancer treatment that is over 20 years in the making.
Archive for the 'Gemcitabine' Category
GemzarÂ® (gemcitabine HCl) is an anticancer drug that interferes with the processes of DNA production; by doing so, Gemzar prevents cancer cells from replicating and thus slows or stops tumor growth.
Lilly Oncology Prepares for Strong Showing at ASCO 2006; Targets Breast Cancer and Other Tumors with 79 Studies: 11 breast cancer studies; 29 thoracic cancer studies; and 8 studies with developing targeted agent
Lilly Oncology, a global leader in thoracic cancer treatment, will be presenting important data on its emerging research in breast cancer therapy at the 42nd annual American Society for Clinical Oncology (ASCO) meeting in Atlanta, Ga., June 2-6, 2006. Among the 79 studies being presented by Lilly Oncology, data from 11 clinical studies focus on
Last update: April 01, 2019. 03:30:08 pm.